Nucleic Acid Therapeutics CDMO Market Size, Share & Growth Graph by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Nucleic Acid Therapeutics CDMO Market Size Analysis

Global Nucleic Acid Therapeutics CDMO Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Cell & Gene Therapies
  1. By Value
3. RNA-based Therapies
  1. By Value
4. mRNA Therapies
  1. By Value
5. siRNA Therapies
  1. By Value
6. Others
  1. By Value
By Service
1. Introduction
  1. Service By Value
2. Process Development & Optimization Services
  1. By Value
3. Manufacturing Services
  1. By Value
4. Analytical & Quality Control Services
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Government & Academic Research Institutes
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Cell & Gene Therapies
  1. By Value
3. RNA-based Therapies
  1. By Value
4. mRNA Therapies
  1. By Value
5. siRNA Therapies
  1. By Value
6. Others
  1. By Value
By Service
1. Introduction
  1. Service By Value
2. Process Development & Optimization Services
  1. By Value
3. Manufacturing Services
  1. By Value
4. Analytical & Quality Control Services
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Government & Academic Research Institutes
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Cell & Gene Therapies
    1. By Value
  3. RNA-based Therapies
    1. By Value
  4. mRNA Therapies
    1. By Value
  5. siRNA Therapies
    1. By Value
  6. Others
    1. By Value
2. By Service
  1. Introduction
    1. Service By Value
  2. Process Development & Optimization Services
    1. By Value
  3. Manufacturing Services
    1. By Value
  4. Analytical & Quality Control Services
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Government & Academic Research Institutes
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Cell & Gene Therapies
  1. By Value
3. RNA-based Therapies
  1. By Value
4. mRNA Therapies
  1. By Value
5. siRNA Therapies
  1. By Value
6. Others
  1. By Value
By Service
1. Introduction
  1. Service By Value
2. Process Development & Optimization Services
  1. By Value
3. Manufacturing Services
  1. By Value
4. Analytical & Quality Control Services
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Government & Academic Research Institutes
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Cell & Gene Therapies
    1. By Value
  3. RNA-based Therapies
    1. By Value
  4. mRNA Therapies
    1. By Value
  5. siRNA Therapies
    1. By Value
  6. Others
    1. By Value
2. By Service
  1. Introduction
    1. Service By Value
  2. Process Development & Optimization Services
    1. By Value
  3. Manufacturing Services
    1. By Value
  4. Analytical & Quality Control Services
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Government & Academic Research Institutes
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Cell & Gene Therapies
  1. By Value
3. RNA-based Therapies
  1. By Value
4. mRNA Therapies
  1. By Value
5. siRNA Therapies
  1. By Value
6. Others
  1. By Value
By Service
1. Introduction
  1. Service By Value
2. Process Development & Optimization Services
  1. By Value
3. Manufacturing Services
  1. By Value
4. Analytical & Quality Control Services
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Government & Academic Research Institutes
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Cell & Gene Therapies
    1. By Value
  3. RNA-based Therapies
    1. By Value
  4. mRNA Therapies
    1. By Value
  5. siRNA Therapies
    1. By Value
  6. Others
    1. By Value
2. By Service
  1. Introduction
    1. Service By Value
  2. Process Development & Optimization Services
    1. By Value
  3. Manufacturing Services
    1. By Value
  4. Analytical & Quality Control Services
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Government & Academic Research Institutes
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Cell & Gene Therapies
  1. By Value
3. RNA-based Therapies
  1. By Value
4. mRNA Therapies
  1. By Value
5. siRNA Therapies
  1. By Value
6. Others
  1. By Value
By Service
1. Introduction
  1. Service By Value
2. Process Development & Optimization Services
  1. By Value
3. Manufacturing Services
  1. By Value
4. Analytical & Quality Control Services
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Government & Academic Research Institutes
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Cell & Gene Therapies
    1. By Value
  3. RNA-based Therapies
    1. By Value
  4. mRNA Therapies
    1. By Value
  5. siRNA Therapies
    1. By Value
  6. Others
    1. By Value
2. By Service
  1. Introduction
    1. Service By Value
  2. Process Development & Optimization Services
    1. By Value
  3. Manufacturing Services
    1. By Value
  4. Analytical & Quality Control Services
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Government & Academic Research Institutes
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Cell & Gene Therapies
  1. By Value
3. RNA-based Therapies
  1. By Value
4. mRNA Therapies
  1. By Value
5. siRNA Therapies
  1. By Value
6. Others
  1. By Value
By Service
1. Introduction
  1. Service By Value
2. Process Development & Optimization Services
  1. By Value
3. Manufacturing Services
  1. By Value
4. Analytical & Quality Control Services
  1. By Value
5. Others
  1. By Value
By End Use
1. Introduction
  1. End Use By Value
2. Pharmaceutical & Biotechnology Companies
  1. By Value
3. Government & Academic Research Institutes
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Cell & Gene Therapies
    1. By Value
  3. RNA-based Therapies
    1. By Value
  4. mRNA Therapies
    1. By Value
  5. siRNA Therapies
    1. By Value
  6. Others
    1. By Value
2. By Service
  1. Introduction
    1. Service By Value
  2. Process Development & Optimization Services
    1. By Value
  3. Manufacturing Services
    1. By Value
  4. Analytical & Quality Control Services
    1. By Value
  5. Others
    1. By Value
3. By End Use
  1. Introduction
    1. End Use By Value
  2. Pharmaceutical & Biotechnology Companies
    1. By Value
  3. Government & Academic Research Institutes
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Nucleic Acid Therapeutics CDMO Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Agilent Technologies, Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Thermo Fisher Scientific Inc.
Danaher
Lonza Group AG
Catalent Inc.
WuXi AppTec Co., Ltd.
Bachem AG
BioSpring GmbH
TriLink BioTechnologies
Eurofins Scientific
Ajinomoto Bio-Pharma Services
AGC Biologics, Inc.
PolyPeptide Group AG
Nitto Denko Avecia Inc.
Kaneka Eurogentec S.A.
LGC Group
KNC Laboratories Co., Ltd.
Merck KGaA
Curia Global Inc.
Asymchem Inc.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment

Appendix

Discussion Guide
Customization Options
Related Reports

Disclaimer

Get This Report

Our Clients:

Hindustan National Glass & Industries Limited

Table Of Content

Download Free Sample

Mitiksha Koul

Research Associate